Author: Pervaiz, Shazib

Source: Current Pharmaceutical Design, Volume 12, Number 34, December 2006 , pp. 4469-4477(9)

Publisher: Bentham Science Publishers

Abstract:

Apoptosis is an essential and highly conserved process for the maintenance of tissue homeostasis and involves a programmed series of events for the removal of effete, damaged, or mutated cells. Although, activation of caspases underscores the classical signaling cascade during apoptotic execution the role of caspase-independent mechanisms in apoptosis has also gained recognition. It is now well established that apoptotic execution is an inherent tumor suppressor mechanism and failure of apoptosis invariably leads to the acquisition of the transformed phenotype. Indeed, resistance to apoptosis is an essential acquired trait that facilitates the processes of tumor initiation and progression. As a matter of fact, efficient death execution could be a critical even at an earlier stage to inhibit tumor promotion. Interestingly, there is a school of thought supported by strong data that an altered redox status and intracellular milieu of cells could provide the seeding ground for tumor promotion and initiation, and at a latter stage tumor maintenance/progression, by blunting cell death signaling. These findings have not only enhanced our understanding of the processes of carcinogenesis and drug resistance but, more importantly provide novel targets for designing strategies to overcome the problem of apoptosis resistance in tumor cells. This review focuses on the pathways of apoptotic execution, and discusses the role of intracellular redox status on cell survival and death signaling in tumor cells.

Keywords: death effector domains (DED); reactive oxygen species (ROS); oligomerization; pro-oxidant state; Carcinogenesis

Document Type: Research article

DOI: http://dx.doi.org/10.2174/138161206779010503

Affiliations: 1: NUS Graduate School for Integrative Sciences and Engineering, Department of Physiology, MD9 #02-05, Yong Loo Lin School of Medicine, National University of Singapore,Singapore 117597.

Publication date: 2006-12-01

More about this publication?

• Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.
  
  Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Pervaiz, Shazib

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers